Name | Value |
---|---|
Revenues | 10.3M |
Cost of Revenue | 9.3M |
Gross Profit | 1.0M |
Operating Expense | 8.8M |
Operating I/L | -9.1M |
Other Income/Expense | -1.3M |
Interest Income | 0.0M |
Pretax | -10.6M |
Income Tax Expense | 0.0M |
Net Income/Loss | -10.6M |
Aziyo Biologics, Inc. is a regenerative medicine company specializing in developing products for the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. Its offerings include CanGaroo, a product designed to reduce infection risk post-surgical implantation of electronic devices, as well as cardiovascular products like ProxiCor, Tyke, and VasCure for tissue repairs and peripheral vasculature reconstruction. The company also provides human tissue-derived bone allografts such as Fiber VBM, ViBone, and OsteGro V, along with SimpliDerm for integumental tissue repair. Additionally, it offers contract manufacturing services for various products to corporate customers.